Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial

Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial

Blog Article

Objective To compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis.Design Prospective wac 4011 parallel randomised controlled open-label superiority trial.Setting 76 community pharmacies across New Zealand between 10 September 2015 and 13 December 2017.

Participants 952 adults randomised within the first 72 hours of a herpes simplex labialis episode.Interventions Random assignment 1:1 to either 5% aciclovir cream or medical grade kanuka honey (90%)/glycerine (10%) cream, both applied five times daily.Outcome measures The primary outcome was time from randomisation to return to normal skin (stage 7).

Secondary outcomes included time from randomisation to stage 4 (open wound), time from stage 4 to 7, maximal pain, time to pain resolution and treatment acceptability.Results Primary outcome variable: Kaplan-Meier-based estimates (95% CI) for the median time in days for return to normal skin were 8 (8 to 9) days for aciclovir and 9 (8 to 9) for honey; HR (95% CI) 1.06 (0.

92 to 1.22), p=0.56.

There were no statistically significant differences beer button down shirts for men between treatments for all secondary outcome variables.No related serious adverse events were reported.Conclusion There was no evidence of a difference in efficacy between topical medical grade kanuka honey and 5% aciclovir in the pharmacy-based treatment of herpes simplex labialis.

Trial registration number ACTRN12615000648527;Post-results.